AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. PMN
  4. [Form 4] ProMIS Neurosciences Inc. Insider Trading Activity

[Form 4] ProMIS Neurosciences Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for ProMIS Neurosciences (PMN) shows 10% owner Michael S. Gordon, via Title 19 Promis LLC, increasing his indirect stake.

  • 25 Jul 2025: Exercised Tranches A鈥揅 warrants (119,800 shares each, total 359,400) at a reduced price of $0.83158 versus original $2.02/$2.50 strikes, lifting common-share holdings to 2,435,029.
  • 29 Jul 2025: Purchased 539,100 new five-year warrants at a purchase price of $0.1875 per warrant; each is exercisable at $1.25 for one common share.

Gordon now holds 345,316 derivative securities plus the common shares noted. The actions signal insider commitment and supply up to 898,500 potential new shares, implying moderate dilution if all warrants are exercised.

Deposito del Modulo 4 per ProMIS Neurosciences (PMN) mostra che Michael S. Gordon, proprietario del 10% tramite Title 19 Promis LLC, ha aumentato la sua partecipazione indiretta.

  • 25 lug 2025: Ha esercitato le opzioni Tranches A鈥揅 (119.800 azioni ciascuna, per un totale di 359.400) a un prezzo ridotto di 0,83158 $ rispetto ai prezzi originali di 2,02 $/2,50 $, portando la sua partecipazione in azioni ordinarie a 2.435.029.
  • 29 lug 2025: Ha acquistato 539.100 nuove opzioni quinquennali al prezzo di 0,1875 $ ciascuna; ciascuna opzione 猫 esercitabile a 1,25 $ per un'azione ordinaria.

Gordon detiene ora 345.316 titoli derivati oltre alle azioni ordinarie indicate. Queste operazioni segnalano l'impegno interno e offrono fino a 898.500 potenziali nuove azioni, implicando una diluizione moderata se tutte le opzioni verranno esercitate.

Presentaci贸n del Formulario 4 para ProMIS Neurosciences (PMN) muestra que Michael S. Gordon, propietario del 10% a trav茅s de Title 19 Promis LLC, ha incrementado su participaci贸n indirecta.

  • 25 de jul 2025: Ejerci贸 las garant铆as Tramos A鈥揅 (119,800 acciones cada una, total 359,400) a un precio reducido de $0.83158 frente a los precios originales de $2.02/$2.50, aumentando su tenencia de acciones comunes a 2,435,029.
  • 29 de jul 2025: 颁辞尘辫谤贸 539,100 nuevas garant铆as a cinco a帽os a un precio de compra de $0.1875 por garant铆a; cada una es ejercitable a $1.25 por acci贸n com煤n.

Gordon ahora posee 345,316 valores derivados adem谩s de las acciones comunes mencionadas. Estas acciones indican compromiso interno y ofrecen hasta 898,500 posibles nuevas acciones, lo que implica una diluci贸n moderada si se ejercen todas las garant铆as.

ProMIS Neurosciences (PMN)鞚� Form 4 鞝滌稖鞐愳劀 10% 靻岇湢欤检澑 Michael S. Gordon鞚� Title 19 Promis LLC毳� 韱淀暣 臧勳爲 歆�攵勳潉 電橂Π 瓴冹溂搿� 雮橅儉雮姷雼堧嫟.

  • 2025雲� 7鞗� 25鞚�: Tranches A鈥揅 鞗岆煱韸�(臧� 119,800欤�, 齑� 359,400欤�)毳� 鞗愲灅 頄夓偓臧� $2.02/$2.50 雽�牍� 頃犾澑霅� $0.83158鞐� 頄夓偓頃橃棳 氤错喌欤� 氤挫湢霟夓潉 2,435,029欤�搿� 歃濌皜鞁滌及鞀惦媹雼�.
  • 2025雲� 7鞗� 29鞚�: 5雲� 毵岅赴 鞁犼窚 鞗岆煱韸� 539,100欤�毳� 欤茧嫻 $0.1875鞐� 毵れ垬; 臧� 鞗岆煱韸鸽姅 氤错喌欤� 1欤茧嫻 $1.25鞐� 頄夓偓 臧�電ロ暕雼堧嫟.

順勳灛 Gordon鞚� 氤错喌欤� 鞕胳棎 345,316臧滌潣 韺岇儩歃濌秾鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 臁办箻電� 雮措秬鞛愳潣 鞚橃毳� 雮橅儉雮措┌, 氇摖 鞗岆煱韸戈皜 頄夓偓霅� 瓴届毎 斓滊寑 898,500欤检潣 鞁犼窚 欤检嫕鞚� 氚滍枆霅橃柎 欷戧皠 鞝曤弰鞚� 頋劃 須臣臧� 鞓堨儊霅╇媹雼�.

D茅p么t du formulaire 4 pour ProMIS Neurosciences (PMN) r茅v猫le que Michael S. Gordon, d茅tenteur de 10% via Title 19 Promis LLC, a augment茅 sa participation indirecte.

  • 25 juil. 2025 : Exercice des bons Tranches A鈥揅 (119 800 actions chacun, total 359 400) 脿 un prix r茅duit de 0,83158 $ contre les prix initiaux de 2,02 $/2,50 $, portant la d茅tention d鈥檃ctions ordinaires 脿 2 435 029.
  • 29 juil. 2025 : Achat de 539 100 nouveaux bons d鈥檜ne dur茅e de cinq ans au prix d鈥檃chat de 0,1875 $ par bon ; chacun est exer莽able 脿 1,25 $ pour une action ordinaire.

Gordon d茅tient d茅sormais 345 316 titres d茅riv茅s en plus des actions ordinaires mentionn茅es. Ces op茅rations t茅moignent d鈥檜n engagement interne et repr茅sentent jusqu鈥櫭� 898 500 actions potentielles nouvelles, impliquant une dilution mod茅r茅e si tous les bons sont exerc茅s.

Formular 4 Einreichung f眉r ProMIS Neurosciences (PMN) zeigt, dass Michael S. Gordon, 10%-Eigent眉mer 眉ber Title 19 Promis LLC, seinen indirekten Anteil erh枚ht hat.

  • 25. Juli 2025: Aus眉bung der Tranches A鈥揅 Warrants (je 119.800 Aktien, insgesamt 359.400) zu einem reduzierten Preis von 0,83158 $ gegen眉ber den urspr眉nglichen Aus眉bungspreisen von 2,02 $/2,50 $, wodurch der Bestand an Stammaktien auf 2.435.029 erh枚ht wurde.
  • 29. Juli 2025: Kauf von 539.100 neuen f眉nfj盲hrigen Warrants zum Kaufpreis von 0,1875 $ pro Warrant; jeder ist zu 1,25 $ f眉r eine Stammaktie aus眉bbar.

Gordon h盲lt nun 345.316 derivative Wertpapiere zus盲tzlich zu den genannten Stammaktien. Diese Ma脽nahmen signalisieren Insider-Engagement und bieten bis zu 898.500 potenzielle neue Aktien, was bei Aus眉bung aller Warrants eine moderate Verw盲sserung bedeuten w眉rde.

Positive
  • Insider confidence: 10% owner exercised 359,400 warrants and bought 539,100 more, increasing exposure to PMN equity.
  • Potential capital infusion: Future exercise of new warrants at $1.25 could supply cash to the company.
Negative
  • Dilution risk: Up to 898,500 additional shares could enter the float if all warrants are exercised.
  • Discounted pricing: Board approved exercise at $0.83158 versus original $2.02鈥�$2.50, suggesting valuation pressure.

Insights

TL;DR: Insider ups stake via discounted warrant exercise; impact modest, signals confidence yet adds dilution risk.

Exercising 359 k warrants at 60鈥�67% below original strikes injects limited cash but strengthens insider ownership above 2.4 m shares. The fresh 539 k $1.25 warrants extend potential capital inflow and share supply over five years. Transactions are routine, with no operational data; market effect likely neutral unless followed by clinical milestones tied to PMN310 that could pull warrants in-the-money sooner.

TL;DR: Large owner negotiated lower exercise prices; governance acceptable if terms offered broadly.

The board鈥檚 acceptance of a sharply reduced strike could raise fairness questions if not equally available to other holders. However, Form 4 shows no preferential information use, and filing timing meets Section 16 requirements. Overall governance risk is low but worth monitoring for future discounted issuances.

Deposito del Modulo 4 per ProMIS Neurosciences (PMN) mostra che Michael S. Gordon, proprietario del 10% tramite Title 19 Promis LLC, ha aumentato la sua partecipazione indiretta.

  • 25 lug 2025: Ha esercitato le opzioni Tranches A鈥揅 (119.800 azioni ciascuna, per un totale di 359.400) a un prezzo ridotto di 0,83158 $ rispetto ai prezzi originali di 2,02 $/2,50 $, portando la sua partecipazione in azioni ordinarie a 2.435.029.
  • 29 lug 2025: Ha acquistato 539.100 nuove opzioni quinquennali al prezzo di 0,1875 $ ciascuna; ciascuna opzione 猫 esercitabile a 1,25 $ per un'azione ordinaria.

Gordon detiene ora 345.316 titoli derivati oltre alle azioni ordinarie indicate. Queste operazioni segnalano l'impegno interno e offrono fino a 898.500 potenziali nuove azioni, implicando una diluizione moderata se tutte le opzioni verranno esercitate.

Presentaci贸n del Formulario 4 para ProMIS Neurosciences (PMN) muestra que Michael S. Gordon, propietario del 10% a trav茅s de Title 19 Promis LLC, ha incrementado su participaci贸n indirecta.

  • 25 de jul 2025: Ejerci贸 las garant铆as Tramos A鈥揅 (119,800 acciones cada una, total 359,400) a un precio reducido de $0.83158 frente a los precios originales de $2.02/$2.50, aumentando su tenencia de acciones comunes a 2,435,029.
  • 29 de jul 2025: 颁辞尘辫谤贸 539,100 nuevas garant铆as a cinco a帽os a un precio de compra de $0.1875 por garant铆a; cada una es ejercitable a $1.25 por acci贸n com煤n.

Gordon ahora posee 345,316 valores derivados adem谩s de las acciones comunes mencionadas. Estas acciones indican compromiso interno y ofrecen hasta 898,500 posibles nuevas acciones, lo que implica una diluci贸n moderada si se ejercen todas las garant铆as.

ProMIS Neurosciences (PMN)鞚� Form 4 鞝滌稖鞐愳劀 10% 靻岇湢欤检澑 Michael S. Gordon鞚� Title 19 Promis LLC毳� 韱淀暣 臧勳爲 歆�攵勳潉 電橂Π 瓴冹溂搿� 雮橅儉雮姷雼堧嫟.

  • 2025雲� 7鞗� 25鞚�: Tranches A鈥揅 鞗岆煱韸�(臧� 119,800欤�, 齑� 359,400欤�)毳� 鞗愲灅 頄夓偓臧� $2.02/$2.50 雽�牍� 頃犾澑霅� $0.83158鞐� 頄夓偓頃橃棳 氤错喌欤� 氤挫湢霟夓潉 2,435,029欤�搿� 歃濌皜鞁滌及鞀惦媹雼�.
  • 2025雲� 7鞗� 29鞚�: 5雲� 毵岅赴 鞁犼窚 鞗岆煱韸� 539,100欤�毳� 欤茧嫻 $0.1875鞐� 毵れ垬; 臧� 鞗岆煱韸鸽姅 氤错喌欤� 1欤茧嫻 $1.25鞐� 頄夓偓 臧�電ロ暕雼堧嫟.

順勳灛 Gordon鞚� 氤错喌欤� 鞕胳棎 345,316臧滌潣 韺岇儩歃濌秾鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 臁办箻電� 雮措秬鞛愳潣 鞚橃毳� 雮橅儉雮措┌, 氇摖 鞗岆煱韸戈皜 頄夓偓霅� 瓴届毎 斓滊寑 898,500欤检潣 鞁犼窚 欤检嫕鞚� 氚滍枆霅橃柎 欷戧皠 鞝曤弰鞚� 頋劃 須臣臧� 鞓堨儊霅╇媹雼�.

D茅p么t du formulaire 4 pour ProMIS Neurosciences (PMN) r茅v猫le que Michael S. Gordon, d茅tenteur de 10% via Title 19 Promis LLC, a augment茅 sa participation indirecte.

  • 25 juil. 2025 : Exercice des bons Tranches A鈥揅 (119 800 actions chacun, total 359 400) 脿 un prix r茅duit de 0,83158 $ contre les prix initiaux de 2,02 $/2,50 $, portant la d茅tention d鈥檃ctions ordinaires 脿 2 435 029.
  • 29 juil. 2025 : Achat de 539 100 nouveaux bons d鈥檜ne dur茅e de cinq ans au prix d鈥檃chat de 0,1875 $ par bon ; chacun est exer莽able 脿 1,25 $ pour une action ordinaire.

Gordon d茅tient d茅sormais 345 316 titres d茅riv茅s en plus des actions ordinaires mentionn茅es. Ces op茅rations t茅moignent d鈥檜n engagement interne et repr茅sentent jusqu鈥櫭� 898 500 actions potentielles nouvelles, impliquant une dilution mod茅r茅e si tous les bons sont exerc茅s.

Formular 4 Einreichung f眉r ProMIS Neurosciences (PMN) zeigt, dass Michael S. Gordon, 10%-Eigent眉mer 眉ber Title 19 Promis LLC, seinen indirekten Anteil erh枚ht hat.

  • 25. Juli 2025: Aus眉bung der Tranches A鈥揅 Warrants (je 119.800 Aktien, insgesamt 359.400) zu einem reduzierten Preis von 0,83158 $ gegen眉ber den urspr眉nglichen Aus眉bungspreisen von 2,02 $/2,50 $, wodurch der Bestand an Stammaktien auf 2.435.029 erh枚ht wurde.
  • 29. Juli 2025: Kauf von 539.100 neuen f眉nfj盲hrigen Warrants zum Kaufpreis von 0,1875 $ pro Warrant; jeder ist zu 1,25 $ f眉r eine Stammaktie aus眉bbar.

Gordon h盲lt nun 345.316 derivative Wertpapiere zus盲tzlich zu den genannten Stammaktien. Diese Ma脽nahmen signalisieren Insider-Engagement und bieten bis zu 898.500 potenzielle neue Aktien, was bei Aus眉bung aller Warrants eine moderate Verw盲sserung bedeuten w眉rde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
GORDON MICHAEL S
(Last) (First) (Middle)
C/O TROVE,
40 BROAD STREET, 8TH FLOOR
(Street)
BOSTON MA 02109
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares, no par value 07/25/2025 X(1) 119,800 A (1) 2,195,429 I By Title 19 Promis(2)
Common Shares, no par value 07/25/2025 X(3) 119,800 A (3) 2,315,229 I By Title 19 Promis(2)
Common Shares, no par value 07/25/2025 X(4) 119,800 A (4) 2,435,029 I By Title 19 Promis(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Tranche A Common Share Purchase Warrants (1) 07/25/2025 X 119,800 (1) (1) Common Shares 119,800 $0 345,316 I See footnote(2)
Tranche B Common Share Purchase Warrants (3) 07/25/2025 X 119,800 (3) (3) Common Shares 119,800 $0 345,316 I See footnote(2)
Tranche C Common Share Purchase Warrants (4) 07/25/2025 X 119,800 (4) (4) Common Shares 119,800 $0 345,316 I See footnote(2)
Warrants to Purchase Common Shares (5) 07/29/2025 P 539,100 (5) (5) Common Shares 539,100 (5) 539,100 I See footnote(2)
Explanation of Responses:
1. On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
2. By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
3. On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
4. On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.
5. On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.
/s/ Michael S. Gordon 07/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many ProMIS Neurosciences shares did Michael S. Gordon acquire on July 25, 2025?

He obtained 359,400 common shares by exercising three warrant tranches.

What was the reduced exercise price for the Tranche A and B warrants?

Both were exercised at $0.83158 per share, down from the original $2.02 strike.

How many new warrants did Title 19 Promis purchase on July 29, 2025?

It bought 539,100 warrants, each exercisable at $1.25 and costing $0.1875 per warrant.

What is Michael S. Gordon鈥檚 total indirect common-share holding after the transactions?

His beneficial ownership increased to 2,435,029 common shares.

Do these transactions affect ProMIS Neurosciences鈥� share count immediately?

Only the 359,400 exercised warrants convert to shares now; the 539,100 new warrants are potential future dilution.
Stock PMN logo
Promis Neuroscie

NASDAQ:PMN

PMN Rankings

#5685 Ranked by Market Cap
N/A Ranked by Dividends

PMN Latest News

Aug 13, 2025
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
Jul 29, 2025
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer鈥檚 Association International Conference
Jul 28, 2025
ProMIS Neurosciences Announces Private Placement Financing
Jul 22, 2025
ProMIS Neurosciences Announces Private Placement Financing
Jul 22, 2025
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

PMN Latest SEC Filings

Aug 13, 2025
[S-8] ProMIS Neurosciences Inc. Employee Benefit Plan Registration
Aug 13, 2025
[S-3] ProMIS Neurosciences Inc. Shelf Registration Statement
Aug 13, 2025
[10-Q] ProMIS Neurosciences Inc. Quarterly Earnings Report
Aug 13, 2025
[8-K] ProMIS Neurosciences Inc. Reports Material Event
Aug 4, 2025
[SCHEDULE 13G] ProMIS Neurosciences Inc. SEC Filing

PMN Stock Data

20.53M
20.53M
28.66%
28.8%
5.41%
Biotechnology
Pharmaceutical Preparations
Canada
TORONTO